{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T19:09:26Z","timestamp":1774724966181,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.ymgme.2009.04.009","type":"journal-article","created":{"date-parts":[[2009,5,5]],"date-time":"2009-05-05T09:23:20Z","timestamp":1241515400000},"page":"278-283","source":"Crossref","is-referenced-by-count":21,"title":["Fabry disease urinary globotriaosylceramide\/creatinine biomarker evaluation by liquid chromatography\u2013tandem mass spectrometry in healthy infants from birth to 6months"],"prefix":"10.1016","volume":"97","author":[{"given":"Caroline","family":"Barr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe T.R.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aim\u00e9","family":"Ntwari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9gen","family":"Drouin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Auray-Blais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2009.04.009_bib1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1056\/NEJM197104082841401","article-title":"Diagnosis of glycosphingolipidoses by urinary-sediment analysis","volume":"284","author":"Desnick","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2009.04.009_bib2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-146-6-200703200-00007","article-title":"Narrative review: Fabry disease","volume":"146","author":"Clarke","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2009.04.009_bib3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10545-006-0196-0","article-title":"Manifestations of Fabry disease in placental tissue","volume":"29","author":"Vedder","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2009.04.009_bib4","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/pd.1767","article-title":"Prenatal diagnosis of Fabry disease","volume":"27","author":"Desnick","year":"2007","journal-title":"Prenat. Diagn."},{"key":"10.1016\/j.ymgme.2009.04.009_bib5","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry\u2019s disease","volume":"372","author":"Zarate","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2009.04.009_bib6","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","article-title":"Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease","volume":"152","author":"Wraith","year":"2008","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2009.04.009_bib7","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","article-title":"Characterization of Fabry disease in 352 pediatric patients in the Fabry registry","volume":"64","author":"Hopkin","year":"2008","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2009.04.009_bib8","article-title":"Natural history of Fabry disease","volume":"vol. 423","author":"Mehta","year":"2006"},{"key":"10.1016\/j.ymgme.2009.04.009_bib9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00428-005-0089-x","article-title":"Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement","volume":"448","author":"Schiffmann","year":"2006","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ymgme.2009.04.009_bib10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/hs0202.102601","article-title":"Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement","volume":"33","author":"Moore","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.ymgme.2009.04.009_bib11","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(05)67636-2","article-title":"Fabry\u2019s disease \u2013 an important risk factor for stroke","volume":"366","author":"Schiffmann","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2009.04.009_bib12","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry registry","volume":"30","author":"Eng","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2009.04.009_bib13","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2005-2895","article-title":"Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease","volume":"118","author":"Ries","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2009.04.009_bib14","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2009.04.009_bib15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1742-1241.2006.01237.x","article-title":"Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature","volume":"61","author":"Lidove","year":"2007","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.ymgme.2009.04.009_bib16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2009.04.009_bib17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10545-006-0444-3","article-title":"Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease","volume":"30","author":"Auray-Blais","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2009.04.009_bib18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ymgme.2007.10.001","article-title":"Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease","volume":"93","author":"Auray-Blais","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2009.04.009_bib19","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10545-007-0607-x","article-title":"Quebec neonatal mass urinary screening programme: from micromolecules to macromolecules","volume":"30","author":"Auray-Blais","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2009.04.009_bib20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10545-009-1055-6","article-title":"Proposed high-risk screening protocol for Fabry disease in patients with renal and vascular disease","volume":"32","author":"Auray-Blais","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2009.04.009_bib21","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1096-7192(03)00136-7","article-title":"Fabry disease: D313Y is an \u03b1-galactosidase A sequence variant that causes pseudodeficient activity in plasma","volume":"80","author":"Froissart","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2009.04.009_bib22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1023\/A:1025115405074","article-title":"Newborn urine screening programme in the province of Quebec: an update of 30 years\u2019 experience","volume":"26","author":"Auray-Blais","year":"2003","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2009.04.009_bib23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00008480-200204000-00006","article-title":"Renal aspects of the term and preterm infant: a selective update","volume":"14","author":"Dukker","year":"2002","journal-title":"Curr. Opin. Pediar."},{"key":"10.1016\/j.ymgme.2009.04.009_bib24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ymgme.2009.01.011","article-title":"Falsely elevated urinary Gb3 (globotriaosylceramide, CTH, GL3)","volume":"97","author":"Forni","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2009.04.009_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10545-005-5263-4","article-title":"Measurement of urinary CDH ant CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease","volume":"28","author":"Mills","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2009.04.009_bib26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-005-4415-x","article-title":"Monitoring enzyme replacement therapy in Fabry disease \u2013 role of urine globotriaosylceramide","volume":"28","author":"Whitfield","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2009.04.009_bib27","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1542\/peds.103.4.e49","article-title":"Why do newborn infants have a high plasma creatinine?","volume":"103","author":"Guignard","year":"1999","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2009.04.009_bib28","first-page":"7","article-title":"Newborn screening for cystic fibrosis: evidence for benefit","volume":"93","author":"Balfour-Lynn","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.ymgme.2009.04.009_bib29","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/S0149-2918(08)80037-9","article-title":"Fabry disease \u2013 Whom to treat and when?","volume":"30","author":"Mehta","year":"2008","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ymgme.2009.04.009_bib30","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s10897-008-9179-7","article-title":"Disease rarity, carrier status, and gender: a triple disadvantage for women with Fabry disease","volume":"17","author":"Gibas","year":"2008","journal-title":"J. Genet. Couns."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719209001085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719209001085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T04:27:48Z","timestamp":1545280068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719209001085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S1096719209001085"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2009.04.009","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}